1. Home
  2. TLSI

as 12-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medical Specialities

Nasdaq

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Founded: 2010 Country:
United States
United States
Employees: N/A City: WESTMINSTER
Market Cap: 124.9M IPO Year: N/A
Target Price: $11.75 AVG Volume (30 days): 52.7K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.41 EPS Growth: N/A
52 Week Low/High: $3.50 - $10.42 Next Earning Date: 11-14-2024
Revenue: $26,891,000 Revenue Growth: 67.90%
Revenue Growth (this year): 60.97% Revenue Growth (next year): 53.69%

TLSI Daily Stock ML Predictions

Share on Social Networks: